Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Despite high enthusiasm, early attempts to develop clinical treatments based on animal research with neurotrophins were not successful. Here we survey clinical trials with neurotrophins, compared with neurotrophic factors of other gene families, and delineate the most likely reasons for their failure. We then suggest improved methods for regulated local supply of NTs to specific populations of neurons and discuss future therapeutic procedures evolving from the more detailed knowledge of the signal transduction pathways activated by neurotrophins via their receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since the discovery of BDNF and its receptor TrkB, efforts have been made to use BDNF as a therapeutic agent for neuropsychiatric disorders or to develop small-molecule pharmaceuticals that could increase the production of BDNF or activate TrkB in brain (for review, see99,100), and these efforts are still ongoing101.”
From Neuronal plasticity and neurotrophic factors in drug responses (2017) · cites this paper as [99]
In the citing paper
“A lack of methods for effectively and safely delivering growth factors to the nervous system over sustained time periods has been a major factor limiting their translational testing32.”
From Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) · cites this paper as [32]
Citations
Cites
Exercise: a behavioral intervention to enhance brain health and plasticity
Cotman, C. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02143-4 · Cited by 2,739 · cited 1×
“New, therapeutically interesting perspectives evolved from the observation that physical exercise evokes a marked increase in BDNF levels in the rat brain, in particular in the hippocampus and cerebral corte”
BackgroundNeurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundNEUROTROPHINS AND SYNAPTIC PLASTICITY
McAllister, A. K., Katz, L. C., & Lo, D. C. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.295 · Cited by 1,337 · cited 1×
“This decisive statement can be made because NTs, besides regulating survival, differentiation and maintenance of neuron-specific characteristics (for example, neurotransmitters and neuropeptides), also are important in modulating activity-dependent neuronal plasticity, essential for the functional and structural refin…”
BackgroundNerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“Although (unregulated) overexpression of neurotrophic molecules by viral vectors has already provided encouraging result”
BackgroundHuang, Z. J., Kirkwood, A., Pizzorusso, T., Porciatti, V., Morales, B., Bear, M. F., Maffei, L., & Tonegawa, S. (1999) · Cell · doi:10.1016/s0092-8674(00)81509-3 · Cited by 1,198 · cited 1×
“For the treatment of neurons that are themselves directly involved in the formation of neuronal circuits, modified in a refined manner by neuronal activity, the local overexpression of NTs could result in functional disturbances, as for example demonstrated in the visual cortex by the local transgenic overexpression o…”
BackgroundHANDBOOK OF EXPERIMENTAL PHARMACOLOGY
Reichlin, S. (1969) · The American Journal of The Medical Sciences · doi:10.1097/00000441-196911000-00008 · Cited by 1,134
Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system
Bibel, M., & Barde, Y.-A. (2000) · Genes & Development · doi:10.1101/gad.841400 · Cited by 1,065
Fischer, W., Wictorin, K., Björklund, A., Williams, L. R., Varon, S., & Gage, F. H. (1987) · Nature · doi:10.1038/329065a0 · Cited by 1,024
Neurotrophic factors: from molecule to man
Lindsay, R. M., Wiegand, S. J., Anthony Altar, C., & DiStefano, P. S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90099-x · Cited by 788 · cited 1×
“Other members of the NT family were linked to a much broader spectrum of biological action”
Background
Research works printed but not linked: 1
- Lowenstein, P.R. & Enquist, L.W. Protocols for Gene Transfer in Neuroscience (Wiley, Chichester, UK, 1996).
Cited by
Items 201–300 of 335
A Simple, Flexible, Nonfluorescent System for the Automated Screening of Neurite Outgrowth
Price, R. D., Oe, T., Yamaji, T., & Matsuoka, N. (2006) · SLAS Discovery · doi:10.1177/1087057105283344 · Cited by 23
Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis
Loeb, J. A. (2007) · Neurology · doi:10.1212/01.wnl.0000275231.97764.43 · Cited by 21
Зайнуллина, Л. Ф., Vakhitova, Y. V., Lusta, A. Y., Гудашева, Т. А., & Середенин, С. Б. (2021) · Scientific Reports · doi:10.1038/s41598-021-87435-0 · Cited by 21
Delayed onset of inherited ALS by deletion of the BDNF receptor TrkB.T1 is non-cell autonomous
Yanpallewar, S. U., Fulgenzi, G., Tomassoni‐Ardori, F., Barrick, C. A., & Tessarollo, L. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113576 · Cited by 20
“A number of questions remain including whether or not BDNF has a sufficient half-life to generate long lasting effects and whether it reaches its target and activates its receptor/s to transduce survival signaling (Thoenen and Sendtner 2002).”
BackgroundArien‐Zakay, H., Lecht, S., Nagler, A., & Lazarovici, P. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11093513 · Cited by 24
“Clinical trials testing the therapeutic properties of various neurotrophic factors have been rather disappointing [68,69].”
Luukko, K., & Kettunen, P. J. (2016) · Cell Adhesion & Migration · doi:10.1080/19336918.2016.1216746 · Cited by 20
Claes, M., Groef, L. D., & Moons, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174314 · Cited by 24
“Neuroprotection does not only entail avoiding the process of apoptosis, it should also secure the recovery of the neuron towards homeostasis [127].”
BackgroundRuiz, R., Lin, J. C., Forgie, A. J., Foletti, D. L., Shelton, D., Rosenthal, A., & Tabares, L. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi189 · Cited by 21
“However, clinical trials had encountered problems such as inadequate dosage, side effects, etc (21, 22).”
Baazaoui, N., & Iqbal, K. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170075 · Cited by 21
Heparanase, TrkC and p75NTR: Their functional involvement in human medulloblastoma cell invasion
Sinnappah-Kang, N. D., Kaiser, A. J., Blust, B. E., Mrak, R. E., & Marchetti, D. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.3.617 · Cited by 20
Kliem, M. A., Heeke, B. L., Franz, C. K., Radovitskiy, I., Raore, B., Barrow, E. M., Snyder, B. R., Federici, T., Spratt, S. K., & Boulis, N. M. (2011) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2011.574142 · Cited by 19
Zafer, D., Aycan, N., Özaydın, B., Kemanli, P., Ferrazzano, P. A., Levine, J. E., & Cengiz, P. (2019) · Neuroendocrinology · doi:10.1159/000499661 · Cited by 20
Hausott, B., Vallant, N., Hochfilzer, M., Mangger, S., Irschick, R., Haugsten, E. M., & Klimaschewski, L. P. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.09.009 · Cited by 21
Bachis, A., & Mocchetti, I. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20780 · Cited by 19
“However, the potential of BDNF as a therapeutic agent in humans has been questioned because of its inability to cross the blood–brain barrier and other problems associated with its delivery to appropriate neuronal populations (Thoenen and Sendtner, 2002).”
BackgroundNew insights into the therapeutic approaches for the treatment of tauopathies
Singh, H., Das, A., Khan, M. M., & Pourmotabbed, T. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385288 · Cited by 20
“These approaches, however, have been slowed by concerns about the specificity, limited BBB permeability, and potential side effects of the available drugs in animal studies (Thoenen and Sendtner, 2002).”
BackgroundAdaptability of the Immature Ocular Motor Control System: Unilateral IGF-1 Medial Rectus Treatment
Willoughby, C. L., Fleuriet, J., Walton, M. M. G., Mustari, M. J., & McLoon, L. K. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16761 · Cited by 18
“A strong advantage of our treatment paradigm is local IGF-1 delivery, which avoids the serious side effects caused by systemic administration of IGF-1.”
BackgroundGirard, M. F., Carrier, P., Loustaud-Ratti, V., & Nubukpo, P. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1833211 · Cited by 18
“and it passes the blood-meningeal barrier (7).”
Hama, Y., Shiraki, K., Yoshida, Y., Maruyama, A., Yasuda, M., Tsuda, M., Honda, M., Takahashi, M., Higuchi, H., Takasaki, I., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02061-09 · Cited by 19
“Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family that plays an important role in the development and plasticity of the peripheral and central nervous systems (3, 37).”
BackgroundFeasibility of cell therapy for amyotrophic lateral sclerosis
Garbuzova-Davis, S. N., & Sanberg, P. R. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.11.004 · Cited by 19
Bowling, H. L., Bhattacharya, A., Klann, E., & Chao, M. V. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.179031 · Cited by 19
“Since BDNF is a large, very basic protein that does not readily penetrate tissues, the application of BDNF was problematic in clinical trials (Thoenen and Sendtner 2002).”
Lang, E. M., Asan, E., Plesnila, N., Hofmann, G. O., & Sendtner, M. (2005) · Plastic & Reconstructive Surgery · doi:10.1097/01.prs.0000163328.51271.dd · Cited by 20
Self-citationHeterogeneity in motoneuron disease
Lambrechts, D., Robberecht, W., & Carmeliet, P. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.07.002 · Cited by 20
Shoji, M., Nishioka, M., Minato, H., Harada, K., Kubo, M., Fukuyama, Y., & Kuzuhara, T. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.092 · Cited by 17
“Moreover, clinical trials of NGF and BDNF have failed [8].”
BackgroundLi, W., Jia, H., Wang, Z., Zhai, F., Sun, G.-D., Ma, D., Liu, G., Li, C., & Wang, Y. (2020) · Journal of Tissue Engineering · doi:10.1177/2041731420980136 · Cited by 17
Neurotrophins and Peripheral Neuropathies
Sahenk, Z. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.00038.x · Cited by 17
“Previously, the potential use of neurotrophins was thought to offer symptomatic treatments, as no human degenerative disorder was directly linked to absence or defective production of neurotrophins or mutations in their receptors (87).”
BackgroundChemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments
Galimberti, D., Bresolin, N., & Scarpini, E. A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.3.439 · Cited by 17
Wang, Y., Su, H., Zhong, J., Zhan, Z., Zhao, Q. P., Liu, Y., Li, S., Wang, H., Yang, C., Yu, L., et al. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00154-y · Cited by 18
“Unfortunately, neurotrophins exhibit limited efficacy in protecting neurons in disease models [45].”
BackgroundCurrent progression in application of extracellular vesicles in central nervous system diseases
Zhang, X., Huang, J., Ni, X.-Y., Zhu, H.-R., Huang, Z., Ding, S., Yang, X., Tan, Y.-D., Chen, J., & Cai, J. (2024) · European journal of medical research · doi:10.1186/s40001-023-01606-5 · Cited by 17
“They are difficult to cross the BBB and have a low half-life in serum, but it can be avoided by BDNF and pre-BDNF on EVs [146–149].”
BackgroundProlonged regulatable expression of EPO from an HSV vector using the LAP2 promoter element
Wu, Z., Mata, M. M., & Fink, D. J. (2011) · Gene Therapy · doi:10.1038/gt.2011.188 · Cited by 16
Marconi, P., Zucchini, S., Berto, E., Bozac, A., Paradiso, B., Bregola, G., Grassi, C., Volpi, I., Argnani, R., Marzola, A., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302438 · Cited by 17
Gene therapy for the treatment of sensory neuropathy
Mata, M. M., Chattopadhyay, M., & Fink, D. J. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.5.499 · Cited by 19
“Despite the impressive effects of trophic factor administration in the treatment of neuropathy in animal models, treatment of patients with these factors has been disappointing [31,48,49].”
BackgroundCapsoni, S., Marinelli, S., Ceci, M., Vignone, D., Amato, G., Malerba, F., Paoletti, F., Meli, G., Viegi, A., Pavone, F., et al. (2012) · PLoS ONE · doi:10.1371/annotation/97b6c799-1ebc-4e7b-8f86-47c1130dc00e · Cited by 16
Ambjørn, M., Dubreuil, V., Miozzo, F., Nigon, F., Møller, B. K., Issazadeh‐Navikas, S., Berg, J., Lees, M. J., & Sap, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065371 · Cited by 15
“In spite of their theoretical potential, NTs as therapeutic agents have had limited success due to poor pharmacokinetics [27] and severe side-effects [28], and thus treatment strategies improving cell intrinsic mechanisms of axon elongation and regeneration would be beneficial.”
BackgroundExploiting the neurotherapeutic potential of peptides: targeted delivery using HSV vectors
Glorioso, J. C., Mata, M. M., & Fink, D. J. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.8.1233 · Cited by 16
“In the past decade, a number of failed clinical trials have made it clear that ‘the indiscriminate flooding of the nervous system with neurotrophins’ cannot be used to treat neurologic disease in patients [3].”
BackgroundBezdjian, A., Kraaijenga, V. J. C., Ramekers, D., Versnel, H., Thomeer, H. G. X. M., Klis, S. F. L., & Grolman, W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121981 · Cited by 14
“The presence of the blood-brain barrier in the CNS preventing proteins with poor pharmacokinetic properties to cross could explain this inefficacy [20,57].”
BackgroundInfluentialFurukawa, K., Fuse, I., Iwakura, Y., Sotoyama, H., Hanyu, O., Nawa, H., Sone, H., & Takei, N. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0505-y · Cited by 13
“Thus, BDNF has been implicated in neurodegenerative diseases and has been tried as a therapeutic intervention for such diseases [2].”
BackgroundVidal‐Villegas, B., Pierdomenico, J. D., Gallego‐Ortega, A., Galindo‐Romero, C., Martínez-de-la-Casa, J. M., García-Feijoo, J., Villegas‐Pérez, M. P., & Vidal‐Sanz, M. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108694 · Cited by 14
Sendtner, M. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-45106-5_15 · Cited by 13
Self-citationCNTF, STAT3 and new therapies for axonal degeneration: what are they and what can they do?
Selvaraj, B. T., & Sendtner, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.9 · Cited by 11
Self-citationFirouzan, B., Iravanpour, F., Abbaszadeh, F., Akparov, V. K., Zaringhalam, J., Ghasemi, R., & Maghsoudi, N. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114585 · Cited by 10
Shoji, M., Ueda, M., Nishioka, M., Minato, H., Seki, M., Harada, K., Kubo, M., Fukuyama, Y., Suzuki, Y., Aoyama, E., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.09.003 · Cited by 10
Chemistry and Neurotrophic Activities of (–)-Talaumidin and Its Derivatives
Harada, K., Kubo, M., & Fukuyama, Y. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00301 · Cited by 9
Neuroprotective effects of flavonoids
Taghizadieh, M., Modiri, N., Salmaninejad, A., Khayami, R., Taheri, F., Moghoofei, M., Khatami, A., Azhdari, S., Bayat, M., Samadi-khouzani, A., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824467-8.00016-4 · Cited by 12
Sharma, A. D., Brodskiy, P., Petersen, E. M., Dağdeviren, M., Ye, E., Mallapragada, S. K., & Sakaguchi, D. S. (2015) · Journal of Visualized Experiments · doi:10.3791/52242 · Cited by 8
Development of Precision Small-Molecule Proneurotrophic Therapies for Neurodegenerative Diseases
Janssens, J., Lu, D., Ni, B., Chadwick, W., Siddiqui, S., Azmi, A. S., Etienne, H., Jushaj, A., van Gastel, J., Martin, B., et al. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.10.006 · Cited by 9
Dipeptide Mimetic of the BDNF Loop 4 Possesses Analgetic Activity
Гудашева, Т. А., Konstantinopolsky, M. A., Тарасюк, А. В., Колик, Л. Г., & Середенин, С. Б. (2019) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672919020121 · Cited by 8
Intracerebral Infusion of Neurotrophic Factors
Hagg, T. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-504-6_12 · Cited by 8
Petruska, J. C., & Mendell, L. M. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00672-0 · Cited by 10
Therapeutic Potential of AAV1-Rheb(S16H) Transduction against Neurodegenerative Diseases
Nam, Y., Moon, G. J., & Kim, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063064 · Cited by 7
Zhou, Q., Tang, H., Bai, D., & Kong, Y. (2022) · PeerJ · doi:10.7717/peerj.12886 · Cited by 8
“However, the poor delivery and short half-life of BDNF in vivo limit its clinical applications (Thoenen & Sendtner, 2002).”
BackgroundDynamic Structure of NGF and proNGF Complexed with p75NTR: Pro-Peptide Effect
Pimenta, A. C., Dourado, D. F. A. R., Martins, J. M. D. S., Melo, A., Cordeiro, M. N. D. S., Almeida, R. D., Morra, G., & Moreira, I. S. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500101n · Cited by 10
Holmes, M., Maysinger, D., Foerster, A. P., Pertens, E., Barlas, C., & Diamond, J. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00217-3 · Cited by 7
Protein Kinase C Regulates the Expression of M1 Receptors and BDNF in Rat Retinal Cells
dos Santos, A. A., Medina, S. V., Martins, L. D. A., & Giestal‐de‐Araujo, E. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9847-x · Cited by 8
“It has been demonstrated that some of these effects are mediated by cytokine release induced by neurotransmitters suggesting a positive and important feedback between these molecules [1].”
Miranda, V., Castiglioni, S., & Maier, J. A. M. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1620894 · Cited by 10
Weyne, E., Hannan, J. L., Gevaert, T., Soebadi, M. A., Matsui, H., Castiglione, F., van Renterghem, K., Ridder, D. J. M. K. D., der Aa, F. V., Bivalacqua, T. J., et al. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.02.013 · Cited by 6
Harper, M. M., Boese, E. A., Kardon, R. H., Ledolter, J., & Kuehn, M. H. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1822417 · Cited by 6
“Target-derived neurotrophic factors are essential for neuronal development and plasticity, to prevent cellular atrophy, enhance neuronal survival, and facilitate axon regeneration in the central nervous system (CNS).(2) In addition to receptors at the axon terminal, RGCs also express neurotrophin receptors on their so…”
BackgroundDesigned NGF mimetics with reduced nociceptive signatures in neuronsPreprint
Schlichthaerle, T., Yang, A., Detraux, D., Johnson, D. E., Peach, C. J., Edman, N. I., Sniezek, C. M., Williams, C. A., Arora, S., Katiyar, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.14.648806 · Cited by 7
Ebert, E. T., Schwinghamer, K., & Siahaan, T. J. (2024) · Life · doi:10.3390/life14111456 · Cited by 10
“Indeed, many clinical trials focusing on the systemic delivery of NGF have failed either due to lack of efficacy or the presence of pain as a side effect [142].”
Chanana, V., Zafer, D., Kintner, D. B., Chandrashekhar, J. H., Eickhoff, J. C., Ferrazzano, P. A., Levine, J. E., & Cengiz, P. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00596-1 · Cited by 5
Inoue, A., Iwasaki, S., Fujimoto, C., Nakajima, T., & Yamasoba, T. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1813-0 · Cited by 5
Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen
Kleinschnitz, C., Meuth, S. G., Kieseier, B. C., & Wiendl, H. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2261-9 · Cited by 11
BRAIN-DERIVED NEUROTROPHIC FACTOR AND ENDOCANNABINOID FUNCTIONS IN GABAERGIC INTERNEURON DEVELOPMENT
Berghuis, P. (2007) · Figshare · Cited by 5
Wei, X., Li, M., You, J., Luo, J., Zhai, J., Zhang, J., Feng, J., Wang, H., & Zhou, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s505677 · Cited by 5
Neurogenesis as a potential therapeutic strategy for neurodegenerative disorders
Kelleher-Andersson, J. A. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6s601 · Cited by 5
“Previous attempts at utilizing naturally occurring proteins, including neurotrophins as CNS therapeutics, have met with considerable difficulties in the clinic as reviewed elsewhere (see [61]).”
Basic Research on Neurotrophic Factors and Its Application to Medical Uses
Furukawa, S. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.15-00219 · Cited by 4
Transplants of CNTF-producing Cells for the Treatment of Huntington's Disease
Escartin, C., Hantraye, P., & Déglon, N. (2007) · Elsevier eBooks · doi:10.1016/b978-012369415-7/50023-5 · Cited by 3
Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System
Wang, X., Su, Y., Hu, X., & Niu, J. (2021) · Journal of Visualized Experiments · doi:10.3791/63343 · Cited by 3
Rakkhitawatthana, V., Sillapachaiyaporn, C., Nilkhet, S., Brimson, J. M., & Tencomnao, T. (2022) · Journal of Associated Medical Sciences · doi:10.12982/jams.2023.010 · Cited by 5
Neumann, S., Kuteykin‐Teplyakov, K. B., & Heumann, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053030 · Cited by 4
“…mimetics are expected to counteract the devastating effects of neurodegenerative disorders of the central nervous system (CNS), involving those of Alzheimer’s disease (AD) or Parkinson’s disease (PD) [2,3], but the development of clinical treatments was not successful in previous attempts [4].”
BackgroundModulation of neurotrophic growth factors as a therapeutic strategy for neuropathic pain
Sah, D. W. Y., Porreca, F., & Ossipov, M. H. (2006) · Drug Development Research · doi:10.1002/ddr.20102 · Cited by 3
“…2006 Wiley-Liss, Inc. to clinical trials where these neurotrophic growth factors were tested as potential therapeutics for diabetic neuropathy, HIV neuropathy, ALS (amyotrophic lateral sclerosis), Huntington’s disease, Alzheimer’s disease, or Parkinson’s disease [Thoenen and Sendtner, 2002].”
Chihara, Y., Iwasaki, S., Kondo, K., & Yamasoba, T. (2011) · Brain Research · doi:10.1016/j.brainres.2011.06.058 · Cited by 4
“Previous attempts to develop clinical treatments with NTFs for neural diseaseswere not successfulmainly due to their poor pharmacokinetics (Thoenen and Sendtner, 2002).”
BackgroundBystander Effect on Brain Tissue of Mesoangioblasts Producing Neurotrophins
Su, T., Scardigli, R., Fasulo, L., Paradiso, B., Barbieri, M., Binaschi, A., Bovolenta, R., Zucchini, S., Cossu, G., Cattaneo, A., et al. (2012) · Cell Transplantation · doi:10.3727/096368912x640475 · Cited by 3
From Cell Death to Neuronal Regeneration: Building a New Brain after Traumatic Brain Injury
Schwab, J. M., Brechtel, K., Conrad, S., & Schluesener, H. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.2.180 · Cited by 3
Non-invasive peripheral delivery of CDNF fragment protects neurons in models of Parkinson’s and ALSPreprint
Yu, L. Y., Viljakainen, T., Beckett, L., Nam, J. H., Hyysalo, A., Lüningschrör, P., Albert, K., Koppinen, T. K., Hyvärinen, T., Tossavainen, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.09.637291 · Cited by 5
Self-citationSharma, A. D., Brodskiy, P., Petersen, E. M., Dağdeviren, M., Ye, E., Mallapragada, S. K., & Sakaguchi, D. S. (2015) · Journal of Visualized Experiments · doi:10.3791/52242-v · Cited by 2
Focused ultrasound: Innovation in use for neurologic conditions
Siyanaki, M. R. H., Pierre, K., Felisma, P., Mampre, D. M., Stein, A., Fusco, A. F., Reddy, R., Chandra, V., & Lucke-Wold, B. P. (2023) · Trauma and Emergency Medicine · doi:10.46439/trauma.1.001 · Cited by 2
Effects of Acupuncture on Peripheral Nerve Regeneration
Chen, Y.-S., Ke, C., Chen, C., & Lin, J. (2018) · Springer eBooks · doi:10.1007/978-981-13-0971-7_6 · Cited by 2
(2007) · Humana Press eBooks · doi:10.1007/978-1-59259-730-7_2 · Cited by 2
Cholinergic Aspects of Growth and Development
General), C. T. T. S. (2007) · Springer eBooks · doi:10.1007/978-0-387-46526-5_8 · Cited by 2
ADULT RAT SPINAL CORD CULTURE ON AN ORGANOSILANE SURFACE IN A NOVEL SERUM-FREE MEDIUM
Das, M., Bhargava, N., Gregory, C., Riedel, L., MOLNAR, P., & Hickman, J. J. (2005) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/0505031.1 · Cited by 2
Semisynthesis of natural products at room temperature
Majhi, S., & Manickam, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15269-6.00006-7 · Cited by 2
Gastrointestinal disorders-induced pain
Singhal, M., Arora, V., & Im, H. (2019) · Gene Reports · doi:10.1016/j.genrep.2019.100580 · Cited by 2
Nose to Brain Delivery of Therapeutic Agents
Vaka, S. R. K. (2011) · Cited by 2
Isenmann, S. (2004) · Springer eBooks · doi:10.1007/1-4020-2541-6_31 · Cited by 2
Shiu, F. H., Skelton, H. M., Berglund, K., Fernandez, A. M., Gutekunst, C., Robinson, E. R., Wang, Z., & Gross, R. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.17.512538 · Cited by 2
“This brought attention whether 6-OHDA or other toxin-mediated PD model are useful in assessing neuroprotective treatments(Thoenen and Sendtner, 2002).”
BackgroundResultInfluentialNetwork mechanism analysis between hippocampal development and Alzheimer's disease
Xu, S., Liu, Z.-T., Yang, X.-Y., Huang-Fu, X., Yue, B., & Tang, X.-H. (2025) · New medicine. · doi:10.61958/nmfu1373 · Cited by 2
Zhang, Y., Zhao, S., Wu, S., Niu, H., Gu, L., & Song, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07804-z · Cited by 1
“…mechanisms: NGF does not effectively enter the cerebral blood-brain barrier after systemic administration, suggesting that it is poorly penetrating [7], and experiments with intranasal administration of NGF in adult SD rats with intact and damaged spinal cord revealed that spinal cord NGF content…”
Burbach, G. J., Hellweg, R., Haas, C. A., Turco, D. D., Deicke, U., Abramowski, D., Jucker, M., Staufenbiel, M., & Deller, T. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80809-1 · Cited by 1
Kilpatrick, T. J., Ransohoff, R. M., & Wesselingh, S. L. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9781139195805.006 · Cited by 1
Wen, T., Chu, J., Cheng, W., Fu, Y., Hu, F., Yang, R., Guo, Y., Zhang, Y., & Liu, J. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127832 · Cited by 1
Strominger, N. L., Demarest, R. J., & Laemle, L. B. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-779-8_2 · Cited by 2
The Mechanism of NGF Signaling Suggested by the p75 and TrkA Receptor Complexes
Bazán, J. F., & Wiesmann, C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00041-3 · Cited by 2
Cengotitabengoa, M. M., Alberich, S., Parellada, M., Cabrera, B., Berrocoso, E., Rodríguez–Jiménez, R., Lobo, A., García‐Portilla, M. P., Bernardo, M., Leza, J. C., et al. (2019) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000561 · Cited by 1
“Also, its pharmacokinetics is unknown [31], as neurotrophins are large proteins with a poor penetration into tissue that cannot enter the blood-brain barrier.”
BackgroundNeurotrophins: Physiology and Pharmacology
Conner, J. M., & Tuszynski, M. H. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00520-9 · Cited by 1
Bloss, E. B., Morrison, J. H., & McEwen, B. S. (2011) · Wiley eBooks · doi:10.1002/9781118083222.ch17 · Cited by 1
Neural crest in development and repair
Aquino, J. B. (2007) · Figshare · Cited by 2
Birnbaum, G., Leist, T. P., & LUBLIN, F. D. (2007) · Neurology · doi:10.1212/01.wnl.0000275226.67269.a3 · Cited by 1
Multiple Sklerose: potenzielle Therapieansätze und Update laufender Studien
Wiendl, H., Lehmann, H. C., Hohlfeld, R., Hartung, H., & Kieseier, B. C. (2004) · Der Nervenarzt · doi:10.1007/s00115-003-1665-4 · Cited by 6
Marshall, F. J. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2261-9.50033-1 · Cited by 1
PTEN Deletion Robustly Boosts BRAF-Driven Intraspinal Sensory Axon RegenerationPreprint
Kim, H., Noristani, H. N., Zhai, J., Manire, M., Li, S., Zhong, J., & Son, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.18.613685 · Cited by 1
Metadata
- Authors
- Thoenen, H., & Sendtner, M.
- Affiliations
- Max Planck Society (DE)
- University of Würzburg (DE)
- ORCID
- Sendtner, Michael
- Venue
- Nature Neuroscience
- Published
- 2002-10-28
- Volume
- 5
- Issue
- S11
- Pages
- 1046-1050
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2058026578
- Cited by
- 336
- References
- 56
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 19 · 2018: 9 · 2017: 11 · 2016: 20 · 2015: 14 · 2014: 10 · 2013: 17 · 2012: 17
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Eli Lilly and Company
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- neurotrophins, neurotrophic factors, clinical trials, treatment failure, neurotrophin receptors, signal transduction, gene therapy
- MeSH terms
- Animals, Central Nervous System Diseases, Clinical Trials as Topic, Drug Evaluation, Drug Industry, Humans, Nerve Growth Factors, Peripheral Nervous System Diseases, Drug Design, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.